United Therapeutics is trading at $566.39, up 4.52%, continuing its momentum from a September 30 patent ruling. - A Delaware court found Liquidia’s YUTREPIA infringed two valid United Therapeutics claims covering inhaled treprostinil for pulmonary hypertension, strengthening UTHR's market position. - The ruling led to Liquidia's stock plunging nearly 50% and United Therapeutics gaining about 13% on September 30. - Today's additional gains are also supported by a BTIG analyst upgrade to Buy and the ongoing $477.6 million accelerated share repurchase program.